AC
Therapeutic Areas
Concept Medical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sirolimus-Coated Balloon (SCB) - en-ABL Series | Coronary Artery Disease, All-comer lesions | Commercial (Post-market) |
| Drug-Eluting Stent (DES) - Ability Series | Coronary Artery Disease in Diabetes Mellitus | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Nanolute Series | De novo lesions, In-Stent Restenosis (ISR), Small Vessel, Bifurcation | Commercial (Post-market) |
| Sirolimus-Coated Balloon (SCB) - DEDICATE Registry | Diabetes Mellitus | Registry |
| Sirolimus-Coated Balloon (SCB) - CUT-DRESS RCT | Diabetes Mellitus (Pre-dilation strategy) | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Transform II | Native Coronary Vessel Disease (vs. EES) | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Titan | Native Coronary Vessel Disease (vs. DES) | Phase 3 |
| Sirolimus-Coated Balloon (SCB) - Hybrid Bifurcation PCI | Coronary Bifurcation Lesion | Phase 3 |
Leadership Team at Concept Medical
SD
Sameer Dani
Principal Investigator (en-ABL Studies)
AL
Azeem Latib
Principal Investigator (Ability RCT)
AA
Alexandre Abizaid
Study Chairperson (Ability Diabetes Global)
SK
Santosh Kumar Sinha
Principal Investigator (en ABL Advance)
LT
Luca Testa
Principal Investigator (DEDICATE)
JS
Jorge Sanz Sanchez
Principal Investigator (CUT-DRESS Studies)